ChromaDex Corporation (CDXC): Price and Financial Metrics

CDXC POWR Grades

• Growth is the dimension where CDXC ranks best; there it ranks ahead of 94.65% of US stocks.
• The strongest trend for CDXC is in Quality, which has been heading up over the past 177 days.
• CDXC's current lowest rank is in the Momentum metric (where it is better than 12.19% of US stocks).

CDXC Stock Summary

• The capital turnover (annual revenue relative to shareholder's equity) for CDXC is 2.98 -- better than 81.87% of US stocks.
• Price to trailing twelve month operating cash flow for CDXC is currently 51.29, higher than 93.33% of US stocks with positive operating cash flow.
• For CDXC, its debt to operating expenses ratio is greater than that reported by just 12.17% of US equities we're observing.
• Stocks that are quantitatively similar to CDXC, based on their financial statements, market capitalization, and price volatility, are IRMD, PMD, SPWR, LPRO, and STIM.
• Visit CDXC's SEC page to see the company's official filings. To visit the company's web site, go to www.chromadex.com.

CDXC Valuation Summary

• In comparison to the median Healthcare stock, CDXC's price/earnings ratio is 159.18% lower, now standing at -15.8.
• CDXC's price/sales ratio has moved down 0.2 over the prior 175 months.

Below are key valuation metrics over time for CDXC.

CDXC Growth Metrics

The year over year net income to common stockholders growth rate now stands at -28.42%.
• Its 2 year revenue growth rate is now at 38.42%.
• Its year over year cash and equivalents growth rate is now at -53.03%.

CDXC's revenue has moved up $6,806,000 over the prior 15 months.

The table below shows CDXC's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-09-30	68.813	-19.714	-20.447
2022-06-30	69.058	-21.893	-28.318
2022-03-31	70.025	-25.956	-27.487
2021-12-31	67.449	-24.163	-27.128
2021-09-30	65.135	-19.197	-27.9
2021-06-30	62.007	-17.123	-23.259

CDXC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• CDXC has a Quality Grade of C, ranking ahead of 67.33% of graded US stocks.
• CDXC's asset turnover comes in at 1.115 -- ranking 18th of 682 Pharmaceutical Products stocks.
• MYGN, REPH, and ENDP are the stocks whose asset turnover ratios are most correlated with CDXC.

The table below shows CDXC's key quality metrics over time.